阿瑞吡坦预防肺癌患者含顺铂化疗的止吐疗效观察

摘要

Objective To assess the antiemetic efficacy and safety of aprepitant in patients with lung cancer receiving cisplatin chemotherapy. Methods Seventy-two patients with lung cancer were randomly divided into treatment group of aprepitant(n=36)and placebo group(n=36), and al of them received ondansetron plus dexamethasone treatment. Acute(at1 day)and delayed(at2-5 days)antiemetic efficacy and adverse effects were observed.Results The total antiemetic rate in treatment group(67.2%)was significantly higher compared with that in placebo group(54.3%, P<0.05). In the delayed period,it was significantly higher in treatment group than in placebo group(70.5% vs55.4%,P<0.05),while there was no statistical difference between two groups in acute period(78.5% vs77.4%,P>0.05).Conclusion Aprepitant can effectively prevent lung cancer patients receiving cisplatin chemotherapy from acute and delayed vomiting,with few adverse reactions.%目的 观察阿瑞吡坦预防肺癌患者含顺铂化疗的止吐疗效和安全性.方法 肺癌患者72例随机分为阿瑞吡坦治疗组36例和安慰剂组36例,两组患者均同时接受昂丹司琼+地塞米松治疗.观察急性(第1天)及延迟性(第2~5天)呕吐控制情况和不良反应.结果 阿瑞吡坦组呕吐控制率为67.2%,高于安慰剂组54.3%(P<0.05),延迟期亦高于安慰剂组(70.5%vs55.4%,P<0.05),急性期两组比较差异无统计学意义(78.5%vs77.4%,P>0.05).结论 阿瑞吡坦可以有效预防肺癌患者含顺铂化疗延迟性呕吐,且不良反应小.